Deerfield (United States)

Recent papers from Deerfield (United States)

1. Assessment and Replication of Surface Analysis Results Require Knowing How a Sample Was Handled: Summary of ISO Standard 20579 Part 2, Documenting and Reporting the Preparation and Mounting of Specimens for AnalysisSurface and Interface Analysis · 2026
2. Aripiprazole once-monthly for patients diagnosed with bipolar I disorder: Number needed to treat, number needed to harm, and likelihood to be helped or harmedJournal of Affective Disorders · 2026
3. Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms (CYP2C19, ABCB1, PON1), Noncompliance, Diet, Smoking, Co-Medications (Including Proton Pump Inhibitors), and Pre-Existent Variability in Platelet FunctionJournal of the American College of Cardiology · 2013
4. Dynamics of circulating monomeric C-reactive protein (mCRP) to predict outcomes with first-line alternating oxaliplatin-based chemotherapy and nivolumab in metastatic microsatellite-stable (MSS) colorectal cancer (CRC).Journal of Clinical Oncology · 2026
5. Toward a Small Molecule Therapy for Angelman Syndrome: Structure–Activity Relationship Studies of 3-Aminopyrazole Phenylacetamides as Paternal Ube3a UnsilencersJournal of Medicinal Chemistry · 2026
6. Brexpiprazole for Agitation in Patients with Alzheimer’s Dementia with and without Co-Occurring Psychosis: Post Hoc Analysis of Short- and Long-Term TrialsNeuropsychiatric Disease and Treatment · 2026
7. Long-Term Reductions in Headache Frequency, Severity, and Disability with Eptinezumab in Adults with Chronic Migraine: Results from the PREVAIL TrialPain and Therapy · 2026
8. Short-Term and Long-Term Safety Analyses of Brexpiprazole for Agitation Associated with Dementia due to Alzheimer’s Disease: Timing and Duration of Adverse EventsDrug Safety · 2026
9. Efficacy of Brexpiprazole in Participants with Agitation Associated with Dementia Due to Alzheimer’s Disease: Pooled Analysis of Randomized Controlled TrialsClinical Drug Investigation · 2026
10. Early and Sustained Shift in Headache Day Frequency Following Eptinezumab Treatment in Adults With Migraine for Whom 2–4 Previous Preventive Treatments Have Failed: A Post Hoc Analysis of the Randomized DELIVER TrialEuropean Journal of Neurology · 2025
11. Real-world effectiveness of eptinezumab in chronic migraine—increase in good days in three subgroups: psychiatric comorbidities, prior subcutaneous anti-calcitonin gene-related peptide therapy, and migraine-associated brain fogThe Journal of Headache and Pain · 2025
12. Real-world effectiveness of eptinezumab in chronic migraine—increase in good days in three subgroups: psychiatric comorbidities, prior subcutaneous anti-calcitonin gene-related peptide therapy, and migraine-associated brain fogThe Journal of Headache and Pain · 2025
13. Associations between good days per month and migraine-related disease impact in the real-world: a post hoc analysis from the REVIEW study of eptinezumab in chronic migraineThe Journal of Headache and Pain · 2025
14. Caring Science as a Mature Solution to Global Healthcare ChallengesJournal of Advanced Nursing · 2025
15. Caudal esophageal twist sign may help in differentiating between 360° gastric dilatation-volvulus and gastric dilatation in dogsJournal of the American Veterinary Medical Association · 2025
16. Physician and professional caregiver perspectives on meaningful change in agitation behaviors in Alzheimer’s dementia: Insights from qualitative interviewsFrontiers in Dementia · 2025
17. Importance of Sample Handling and Preparation for Surface Analysis: A Summary of ISO Standard 20579 Part 1, Documenting and Reporting the Handling of Specimens Prior to AnalysisSurface and Interface Analysis · 2025
18. Brexpiprazole for agitation in clinically relevant patient subgroups: a post hoc analysis of efficacy and safety in patients with agitation associated with dementia due to Alzheimer’s diseaseCurrent Medical Research and Opinion · 2025
19. Frequency of anticholinergic drug use in patients treated with aripiprazole once-monthly: a 2-year cohort study using European healthcare databasesTherapeutic Advances in Psychopharmacology · 2025
20. Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Bexicaserin in Healthy Participants: A First‐in‐Human Randomized, Double‐Blind, Placebo‐Controlled Single Ascending Dose Escalation Phase 1 StudyClinical Pharmacology in Drug Development · 2025